Archive for February, 2016
(SAGE) to Present at the 2016 Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 03, 2016 — SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the 2016 Leerink Global Healthcare Conference at 3:55 PM ET on Wednesday, February 10, 2016, in New York City.
A live webcast of the presentation can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage’s website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage’s lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
Investor Contact: Paul Cox, Sage Therapeutics paul.cox@sagerx.com 617-299-8377 Media Contact: Maureen L. Suda, Suda Communications LLC maureen_suda@yahoo.com 585-387-9248
(MOBL) Appoints Daniel Fields SVP of Engineering and Chief Software Development Officer
MOUNTAIN VIEW, Calif., Feb. 4, 2016 — MobileIron (NASDAQ: MOBL), the leader in mobile enterprise security, today announced that Daniel Fields has been named Senior Vice President of Engineering and Chief Software Development Officer. He will report to CEO Barry Mainz.
Daniel takes over engineering from MobileIron co-founder Suresh Batchu. Suresh will continue as Chief Technology Officer, leading MobileIron’s research division that anticipates and develops new technologies to support customers’ mobile initiatives now and in the future.
An experienced engineering leader, Daniel has more than 25 years of experience scaling engineering organizations, leading teams based around the world, and building complex enterprise cloud and on-premises solutions. He joins MobileIron from Oracle where he was Group Vice President, Engineering, Oracle Service Cloud. Before joining Oracle, Daniel was at RightNow Technologies where he served as Vice President, Engineering for the RightNow Service Cloud. Daniel joined Oracle when the company acquired RightNow Technologies for approximately $1.5 billion. At both Oracle and RightNow, Daniel was responsible for building cloud-based applications used in some of the world’s largest contact centers. He was also responsible for technical due diligence on multiple cloud-based acquisitions. Prior to RightNow Technologies, Daniel spent 17 years at Oracle in a variety of engineering roles. He earned a Bachelor of Engineering degree in Electronic Engineering from Dublin City University in Ireland.
“Danny brings an unrivaled combination of engineering skills and leadership as well as the personal experience of driving both a product and a company through rapid growth and I am very pleased to have him on my leadership team,” said Barry Mainz. “Danny’s experience is exactly what we need as MobileIron moves to its next phase of growth.”
“I am really excited to be joining MobileIron to lead the engineering team,” said Daniel Fields. “I am very impressed by this world-class team that has developed the industry-leading suite of mobile security products used by over 10,000 customers. We will focus on delivering highly secure, highly scalable, and highly available innovative solutions that enable organizations to embrace mobile and cloud solutions to drive business efficiency and growth.”
About MobileIron
MobileIron provides the secure foundation for companies around the world to transform into Mobile First organizations. For more information, please visit www.mobileiron.com.
(VHC) Awarded $625.6 Million Verdict Against Apple
Jury Found Apple’s modified VPN On-Demand, iMessage and FaceTime services infringed VirnetX’s patents
ZEPHYR COVE, Nev., Feb. 4, 2016 — VirnetX™ Holding Corporation (NYSE MKT: VHC), an Internet security software and technology company, announced today a jury in the United States Court for the Eastern District of Texas, Tyler Division, in the case VirnetX Inc., et al. v. Apple Inc., No. 6:12-cv-00855, has awarded VirnetX $625.6 million in a verdict against Apple Corporation for infringing four VirnetX patents, marking the second time a federal jury has found Apple liable for infringing VirnetX’s patented technology.
The verdict includes royalties awarded to VirnetX based on an earlier patent infringement finding against Apple. The jury found that Apple’s modified VPN On-Demand, iMessage and FaceTime services infringed VirnetX’s patents and that Apple’s infringement was willful.
In addition to determining the royalty owed by Apple for its prior infringement, today’s verdict also includes an award based on the jury’s finding that Apple’s modified VPN On Demand, iMessage and FaceTime services have continued to infringe VirnetX’s patents.
“We are extremely pleased with the jury verdict,” said Kendall Larsen, VirnetX CEO and President. “The jury agreed once again that Apple has been using the technology developed by our inventors.”
About VirnetX
VirnetX Holding Corporation is an Internet security software and technology company with patented technology for secure communications including 4G LTE security. The Company’s software and technology solutions, including its secure domain name registry and Gabriel Connection Technology™, are designed to facilitate secure communications and to create a secure environment for real-time communication applications such as instant messaging, VoIP, smart phones, eReaders and video conferencing. The Company’s patent portfolio includes over 112 U.S. and international patents and over 75 pending applications. For more information, please visit www.virnetx.com
Forward Looking Statements
Statements in this press release that are not statements of historical or current fact, including statements regarding the strength of VirnetX’s intellectual property, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on expectations, estimates and projections about the markets in which the Company operates, management’s beliefs, and certain assumptions made by management and involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements, including but not limited to (1) the outcome of any legal proceedings that have been or may be initiated by the Company or that may be initiated against the Company, including pending and future inter partes review proceedings in the Patent and Trademark Office; (2) the ability to capitalize on the Company’s patent portfolio and generate licensing fees and revenues; (3) the ability of the Company to be successful in entering into licensing relationships with its targeted customers on commercially acceptable terms; (4) potential challenges to the validity of the Company’s patents underlying its licensing opportunities; (5) the ability of the Company to achieve widespread customer adoption of the Company’s Gabriel Communication Technology™ and its secure domain name registry; (6) the level of adoption of the 3GPP Series 33 security specifications; (7) whether or not the Company’s patents or patent applications may be determined to be or become essential to any standards or specifications in the 3GPP LTE, SAE project or otherwise; (8) the extent to which specifications relating to any of the Company’s patents or patent applications may be adopted as a final standard, if at all; and (9) the possibility that Company may be adversely affected by other economic, business, and/or competitive factors. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” or “plans” to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading “Risk Factors” in Company’s Quarterly Report on Form 10-Q filed with the SEC on November 9, 2015. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s ability to control or predict. Except as required by law, the Company is under no duty to update any of the forward-looking statements after the date of this press release to conform to actual results.
Contact:
Investor Relations
VirnetX Holding Corporation
775.548.1785
ir@virnetx.com
VirnetX, Gabriel Collaboration Suite, Gabriel Secure Communications Platform and GABRIEL Connection Technology are trademarks of VirnetX Holding Corporation. Other company and product names may be trademarks of their respective owners.
(TINY) Portfolio Company, Magic Leap, Raises $793.5 Million in New Funding
NEW YORK, Feb. 03, 2016 — Harris & Harris Group, Inc. (NASDAQ:TINY), an investor in transformative companies enabled by disruptive science, notes the announcement by its portfolio company, Magic Leap, of the close of $793.5 million of new funding led by Alibaba Group. Other new investors in the company include Warner Bros., Fidelity Management and Research Company, J.P. Morgan Investment Management, Morgan Stanley Investment Management, funds and accounts advised by T. Rowe Price Associates, Inc., and Wellington Management Company. Magic Leap’s press release on the round of financing can be viewed at http://www.magicleap.com/#/press/magic-leap-series-c-funding.
About Harris & Harris Group
Harris & Harris Group is a publicly traded venture capital firm that is also a business development company. Detailed information about Harris & Harris Group and its holdings can be found on its website at www.HHVC.com, on Facebook at www.facebook.com/harrisharrisvc and by following on Twitter @harrisandharrisgroup.
This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company’s current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company’s business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company’s actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references and links to the websites www.HHVC.com, www.magicleap.com and www.Facebook.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.
Press Contact: Daniel B. Wolfe Harris & Harris Group, Inc. 212-582-0900
(SKLN) to Present at Source Capital Group’s 2016 Conference
MINNEAPOLIS, Feb. 03, 2016 — Skyline Medical Inc. (NASDAQ:SKLN) (NASDAQ:SKLNU) today announced that Josh Kornberg, President and CEO, will provide a company overview at the Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference at The Convene in New York City. The Company will present at 1:00pm ET on Thursday, February 11, 2016. For more information on the conference or for investors to register, please go to www.SourceCapitalConference.com.
About Skyline Medical Inc.
Skyline Medical Inc. produces a fully automated, patented, FDA-cleared, waste fluid disposal system that virtually eliminates staff exposure to blood, irrigation fluid and other potentially infectious fluids found in the healthcare environment. Antiquated manual fluid handling methods — which require hand carrying and emptying filled fluid canisters — present an exposure risk and potential liability. Skyline Medical’s STREAMWAY System fully automates the collection, measurement and disposal of waste fluids and is designed to: 1) reduce overhead costs to hospitals and surgical centers, 2) improve compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines, 3) improve efficiency in the operating room, and radiology and endoscopy departments — leading to greater profitability, and 4) provide greater environmental stewardship by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United States. For additional information, please visit: www.skylinemedical.com.
About Source Capital Group
Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client’s needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. We have grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to our investment banking activity. http://www.sourcegrp.com
Investor and Media Contact: Garth Russell KCSA Strategic Communications 212-896-1250 skyline@kcsa.com
(MARA) Subsidiary, Orthophoenix LLC Receives Favorable Markman Ruling
LOS ANGELES, CA–(Feb 3, 2016) – Marathon Patent Group, Inc. (NASDAQ: MARA) (“Marathon” or the “Company”), a patent licensing company, announced today that on February 2, 2015, the United States District Court for the District of Delaware issued the claim construction order in the litigation involving its wholly-owned subsidiary Orthophoenix LLC, in its case against Dfine Inc., Wright Medical Technology Inc., and Stryker Corporation.
In his opinion, Chief Judge Leonard P. Stark, addressed disputed claim terms for U.S. Patent numbers 6,440,138 (“the ‘138 patent”), 6,863,672 (“the ‘672 patent”) 6,663,647 (“the ‘647 patent”) 6,248,110 (‘the ‘110 patent”), 6,981,981 (“the ‘981 patent”), and 7,044,954 (“the ‘954 patent”). For all but one of the disputed claim terms, the court issued a favorable claim construction adopting the constructions (or minor variations thereof) proposed by Orthophoenix. The Court rejected defendants’ arguments that the claims were invalid for indefiniteness, and rejected defendants’ attempts to import limitations into the claims in order to avoid infringement.
Doug Croxall, Chief Executive Officer of Marathon, stated, “The Markman order is very encouraging, especially considering that almost all disputed terms were construed in our favor. We were gratified that the Court construed the claims to give them their full scope, and upheld the claims against defendants’ invalidity arguments. It’s rulings like this that generally have the potential to motivate possible resolution in the form of a reasonable licensing agreement. Absent such, we will confidently continue to work towards trial.”
Russ, August & Kabat is representing Orthophoenix. The complete Markman Order may be found at the company’s website.
About Marathon Patent Group
Marathon is a patent acquisition and monetization company. The Company acquires patents from a wide-range of patent holders from individual inventors to Fortune 500 companies. Marathon’s strategy of acquiring patents that cover a wide-range of subject matter allows the Company to achieve diversity within its patent asset portfolio. Marathon generates revenue with its diversified portfolio through actively managed concurrent patent rights enforcement campaigns. This approach is expected to result in a long-term, diversified revenue stream. To learn more about Marathon Patent Group, visit www.marathonpg.com.
Safe Harbor Statement
Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The claim construction described in this press release does not result in revenue for the Company, does not assure success in the pending litigation nor is it binding on an appelate court. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
CONTACT INFORMATION
Marathon Patent Group, Inc.
Jason Assad
678-570-6791
Jason@marathonpg.com
(CNAT) FDA Grants Conatus Fast Track Designation
Focusing on Initial Registration in NASH Cirrhosis With Parallel Development in NASH Fibrosis
SAN DIEGO, Feb. 03, 2016 — Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH). Based on additional communications with the FDA recommending single-etiology clinical trials, the company plans to focus on advancing toward initial registration of emricasan for patients with NASH cirrhosis, with parallel development toward registration of emricasan for patients with NASH fibrosis, and supportive clinical trials addressing additional patient populations.
The Fast Track program provides for greater access to FDA to facilitate development and expedite review of drugs that have demonstrated the potential to treat serious or life-threatening conditions. “The data from our recently completed Portal Hypertension trial, showing clinically meaningful reductions in hepatic venous pressure gradient (HVPG) in patients with severe portal hypertension after only one month of treatment with emricasan, were a key component of our Fast Track submission,” said Conatus co-founder, President and Chief Executive Officer Steven J. Mento, Ph.D. “The Fast Track designation formalizes the recognition of emricasan’s potential to address a significant unmet medical need, but we believe its real importance is in the opportunity for even closer interactions with the FDA as we pursue the most efficient pathway to provide a potentially disease-modifying treatment to patients with NASH cirrhosis.”
About Emricasan Clinical Development
To date, emricasan has been studied in over 650 subjects in sixteen clinical trials across a broad range of liver disease etiologies and stages of progression. In multiple clinical trials, emricasan has demonstrated statistically significant, rapid and sustained reductions in elevated levels of key biomarkers of inflammation and apoptosis that are implicated in the progression of liver disease. Recent clinical trial results have demonstrated emricasan’s ability to provide statistically significant improvements in clinically important validated functional surrogate endpoints of portal hypertension and liver function across a variety of etiologies in the subgroups of liver cirrhosis patients with highest medical need. In November 2015, the company announced plans to conduct a set of parallel EmricasaN, a Caspase inhibitOR, for Evaluation (ENCORE) clinical trials designed to evaluate multiple doses of emricasan over various treatment durations in chronic liver disease of different etiologies and disease stages. The ENCORE trials are designed to provide further information on doses leading to clinically relevant efficacy, including improvement in biopsy-proven fibrosis and inflammation in patients with NASH fibrosis, and improvement in severe portal hypertension and hepatic function in patients with NASH cirrhosis. The ENCORE trials are also designed to provide safety data to support the initial registration of emricasan for chronic administration in patients with liver cirrhosis. The company’s recently initiated Phase 2b ENCORE-NF clinical trial is evaluating emricasan’s potential longer-term benefits for patients with liver fibrosis resulting from NASH. The company also is evaluating emricasan’s potential longer-term benefits on liver fibrosis and cirrhosis in its ongoing Phase 2b clinical trial in post-orthotopic liver transplant (POLT) recipients who developed liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection and who have successfully achieved a sustained viral response (SVR) following antiviral therapy (POLT-HCV-SVR).
About Conatus Pharmaceuticals
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients with chronic liver disease. Emricasan is a first-in-class, orally active pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the disease progression across the spectrum of liver disease. For additional information, please visit www.conatuspharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward looking statements, including statements regarding: the company’s focus on initial registration of emricasan for patients with NASH cirrhosis; development toward registration of emricasan for patients with NASH fibrosis; supportive clinical trials addressing additional patient populations; emricasan’s potential to address a significant unmet medical need; the opportunity for closer interactions with the FDA; emricasan’s disease-modifying potential as a treatment for patients with NASH cirrhosis; the company’s plans to conduct the ENCORE set of parallel clinical trials; the ability of the ENCORE trials to provide dosing information leading to clinically relevant efficacy in patients with NASH fibrosis and NASH cirrhosis, and safety data to support the initial registration of emricasan for chronic administration; emricasan’s potential longer-term benefits for patients with NASH fibrosis; emricasan’s potential longer-term benefits on liver fibrosis and cirrhosis in POLT-HCV-SVR patients; and emricasan’s potential to interrupt the disease progression across the spectrum of liver disease. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including: Conatus’ ability to initiate and successfully complete current and future clinical trials; and those risks described in Conatus’ prior press releases and in the periodic reports it files with the Securities and Exchange Commission. The events and circumstances reflected in Conatus’ forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, Conatus does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
MEDIA: David Schull Russo Partners, LLC (858) 717-2310 David.Schull@RussoPartnersLLC.com INVESTORS: Alan Engbring Conatus Pharmaceuticals Inc. (858) 376-2637 aengbring@conatuspharma.com
(GLUU) With Global Superstar Taylor Swift On New Mobile Game
Hot off her critically acclaimed The 1989 World Tour – Swift embarks on a new adventure in mobile gaming
Glu Mobile Inc. (NASDAQ:GLUU), a leading global developer and publisher of free-to-play games for smartphone and tablet devices, today announced the company has partnered with GRAMMY award-winning artist, Taylor Swift, on the development of a new mobile game. Swift will work exclusively with Glu as part of a multi-year partnership to develop and create a new, one-of-a-kind digital gaming experience. This is Swift’s first foray into the mobile gaming space following her 2015 Emmy award win for Best Original Interactive Program.
“Bringing with her over 227 million social followers*, I am thrilled to welcome Taylor Swift, an award-winning singer, musician and songwriter, to Glu’s family,” said Niccolo de Masi, Glu Chairman and CEO. “We realize that Taylor and her global fan base expect a new and highly differentiated mobile gaming experience,” continued de Masi. “Glu is equally committed to designing never before seen gameplay elements that utilize Taylor’s unique creativity. Accordingly, we will spend the required development time to ensure this innovation is achieved.”
Taylor Swift’s achievements have been recognized industry-wide, which include seven GRAMMY awards, 19 American Music Awards, 11 Country Music Association awards, 9 Academy of Country Music awards, 22 Billboard Music awards, one Brit award, one Emmy award, and 25 Teen Choice Awards. She is the only woman in history to be named Billboard Magazine’s ‘Woman of the Year’ twice, in 2011 and most recently in 2014. In 2015, she was named one of Time Magazine’s ‘100 Most Influential People in the World.’ In the fall of 2014, Swift released her fifth studio album, 1989, which sold 1.3 million copies in its first week making it the top-selling album of the year and Swift is the only artist in history to have three albums sell over one million albums their debut week. By the close of 2015, Taylor Swift had sold over 40 million albums worldwide during the course of her extraordinary career.
Currently slated for global release in late 2016, Glu will provide additional details regarding the game’s development and Taylor Swift’s involvement at a later date.
* Taylor Swift’s social audience as of February 2, 2016: 74 million on Facebook, 70.4 million on Twitter, 64.8 million on Instagram, and 18 million on Vevo. There is some fan overlap among these social channels.
About Glu Mobile
Glu Mobile (NASDAQ:GLUU) is a leading global developer and publisher of free-to-play games for smartphone and tablet devices. Glu is focused on creating compelling original IP games such as CONTRACT KILLER, COOKING DASH, DEER HUNTER, DINER DASH, DINO HUNTER: DEADLY SHORES, ETERNITY WARRIORS, FRONTLINE COMMANDO, RACING RIVALS, TAP SPORTS BASEBALL and TAP SPORTS FOOTBALL, and branded IP games including KIM KARDASHIAN: HOLLYWOOD, KATY PERRY POP, JAMES BOND: WORLD OF ESPIONAGE, MISSION IMPOSSIBLE: ROGUE NATION, and SNIPER X WITH JASON STATHAM on the App Store, Google Play, Amazon Appstore, Facebook, Mac App Store, and Windows Phone. Glu’s unique technology platform enables its titles to be accessible to a broad audience of consumers globally. Founded in 2001, Glu is headquartered in San Francisco with major U.S. offices outside Seattle and in Long Beach, and international locations in Canada, China, India, Japan, Korea, and Russia. Consumers can find high-quality entertainment wherever they see the ‘g’ character logo or at www.glu.com. For live updates, please follow Glu via Twitter at www.twitter.com/glumobile or become a Glu fan at www.facebook.com/glumobile.
CONTRACT KILLER, COOKING DASH, DEER HUNTER, DINER DASH, DINO HUNTER: DEADLY SHORES, ETERNITY WARRIORS, FRONTLINE COMMANDO, RACING RIVALS, SNIPER X, TAP SPORTS BASEBALL, TAP SPORTS FOOTBALL, GLU, GLU MOBILE and the ‘g’ character logo are trademarks of Glu Mobile Inc. or its subsidiaries.
Cautions Regarding Forward-Looking Statements
This release contains certain “forward-looking statements” related to Glu’s efforts to develop and create a new, one-of-a-kind, highly differentiated digital gaming experience; Glu’s commitment to ensuring that it creates a game with never before seen gameplay elements and the expected launch date of this game. Such forward-looking statements involve known and unknown risks and uncertainties, including the risk that Glu does not realize the expected benefits from its agreement with its newly signed celebrity or that Glu is unable to capitalize on her social media following; the risk that consumer demand for mobile devices does not grow as significantly as Glu anticipates or that it is unable to capitalize on any such growth; and the risk of product delays. Certain of these risks and uncertainties are described in greater detail in Glu’s public filings with the SEC. Glu is not under obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
About Taylor Swift
In the fall of 2014, when Taylor Swift released her critically acclaimed fifth album, 1989, she astounded the world by selling almost 1.3 million albums in its debut week — a feat that had been called impossible. Taylor is the only artist in history to have three albums selling over one million copies in their first week of release (2010’s Speak Now, 2012’s RED and 2014’s 1989). Taylor, a seven-time GRAMMY winner, is a singer, musician and songwriter, and the youngest winner in history of the music industry’s highest honor, the GRAMMY Award for Album of the Year and the inaugural recipient of AMA’s Dick Clark Award for Excellence. Taylor has an album on Rolling Stone’s prestigious The 50 Greatest Albums of All Time (by women) list, she is Billboard’s youngest-ever Woman of the Year and the only artist to have been awarded this honor twice, Time magazine has named her one the of the 100 Most Influential People in the world and one of only eight candidates for their most prestigious honor, 2014 Person of the Year. Taylor has career record sales of over 40 million albums and more than 130 million song downloads worldwide, with singles topping the charts around the globe. “Out Of The Woods” is her sixth and current single off 1989, her GRAMMY nominated Album of the Year.
Media:
Glu Mobile Inc.
Jason Enriquez, 415-800-6263
PR@glu.com
or
Taylor Swift
Premium PR
Tree Paine
tree.paine@premiumpr.com
(VTNR) Sells Nevada Facility for $35 Million
Vertex Energy, Inc. (NASDAQ:VTNR), an environmental services company that recycles industrial waste streams and off-specification commercial chemical products, announced today that it has sold its Nevada re-refinery facility, which is located in Churchill County, to Clean Harbors, Inc. for $35 million, of which approximately $14 million was immediately used at closing to purchase the facility and equipment previously leased by Vertex Energy in order to facilitate such sale.
Benjamin P. Cowart, Chairman and CEO of Vertex Energy, said, “This transaction benefits Vertex Energy in a variety of ways, not the least of which is by strengthening our balance sheet. As we noted in our third quarter Form 10-Q filing and on the conference call that followed, the Churchill County facility had an average carrying cost of $1.5 million per quarter. We eliminate those costs with this transaction. At the end of the third quarter of 2015, our cash and cash equivalents were over $4 million. This sale and related transactions will bring that cash position to more than $10 million. We also used $16 million of sale proceeds to pay down our term debt.”
Mr. Cowart added, “While the sale of our re-refinery in Nevada will lessen our footprint in the western U.S., the swap agreement and base oil agreements that were entered into as part of the sale should allow us to improve logistic costs and provide us with a long-term off-take agreement for base oil and finished lubricants to support our business strategy going forward.”
Mr. Cowart concluded, “We intend to put this cash to work both in reducing our long-term debt and in making opportunistic acquisitions. As of the end of the third quarter, the amount of our term debt owed to Goldman Sachs stood at $23.2 million. We have used $16 million of the funds from the Nevada sale to pay down and service that debt, lowering the amount owed to approximately $7 million today and our total long-term debt to approximately $14 million. Additionally, moving forward, we intend to expand our street collections of used oil through acquisitions, thereby decreasing our reliance on third-party purchases. We also anticipate seeing an increase in our margins by moving from third-party purchases to our own collections.”
Clean Harbors’ Chief Operating Officer Eric W. Gerstenberg said, “The Nevada facility is strategically located and aligns with our plans to increase our re-refining presence in California and other West Coast lubricant markets. As we pursue our closed loop direct sales strategy, this plant provides an opportunity to scale our blended operations in the Western U.S. where we currently have no capability. We are confident that the facility will complement our existing re-refining network through transportation efficiencies, additional storage and processing capabilities.”
Houlihan Lokey acted as the exclusive financial advisor to Vertex Energy, Inc. and Reinhart Boerner Van Deuren s.c. provided legal representation.
More information regarding the sale and related transactions can be found in Vertex Energy’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 3, 2016.
ABOUT VERTEX ENERGY, INC.
Vertex Energy, Inc. (NASDAQ: VTNR) is a leading environmental services company that recycles industrial waste streams and off-specification commercial chemical products. Its primary focus is recycling used motor oil and other petroleum by-product streams. Vertex Energy purchases these streams from an established network of local and regional collectors and generators. Vertex Energy also manages the transport, storage and delivery of the aggregated feedstock and product streams to end users, and manages the re-refining of a portion of its aggregated petroleum streams in order to sell them as higher-value end products. Vertex Energy sells its aggregated petroleum streams as feedstock to other re-refineries and fuel blenders or as replacement fuel for use in industrial burners. The re-refining of used motor oil that Vertex Energy manages takes place at its facility, which uses a proprietary Thermal Chemical Extraction Process (“TCEP”) technology. Based in Houston, Texas, Vertex Energy also has offices in California, Chicago, Georgia, and Ohio. More information on Vertex Energy can be found at www.vertexenergy.com.
This press release may contain forward-looking statements, including information about management’s view of Vertex Energy’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of Vertex Energy, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents Vertex Energy files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on Vertex Energy’s future results. The forward-looking statements included in this press release are made only as of the date hereof. Vertex Energy cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Vertex Energy undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Vertex Energy.
Vertex Energy, Inc.
Investor Relations Contact
Marlon Nurse, DM, 212-564-4700
Senior VP – Investor Relations
(VYGR) Promotes Jeff Goater to CFO
CAMBRIDGE, Mass., Feb. 02, 2016 — Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced it has promoted Jeff Goater, former senior vice president of finance and business development, to chief financial officer. In this new role, Mr. Goater will be responsible for overseeing the company’s financial strategy and planning, investor and public relations, corporate operations and business development.
“Jeff’s exceptional leadership has been and will continue to be instrumental in identifying strategic growth opportunities for Voyager,” said Steven Paul, M.D. president and CEO of Voyager Therapeutics. “Since the company’s inception in 2014, Jeff has been a highly regarded member of the leadership team and this promotion is a reflection of his significant contributions to the company’s growth, including Voyager’s successful initial public offering in November 2015.”
Mr. Goater has more than 15 years of business development and financial experience in the biotech industry. He has served in several executive roles since Voyager’s launch in 2014, including senior vice president of finance and business development and vice president of business development. Prior to Voyager, Mr. Goater spent nearly a decade on Wall Street, most recently as a managing director at Evercore Partners, focused on strategic advisory in the life sciences sector. While at Evercore, he advised on more than $100 billion in M&A and licensing transactions. Mr. Goater began his Wall Street career as an equity research analyst at Cowen and Company, covering the biopharmaceutical sector. Prior to Cowen, he worked in biotech business development and began his career as a research scientist in the fields of musculoskeletal biology and gene therapy. Mr. Goater holds a B.A. in biology, an M.S. in pathology/molecular medicine, an M.S. in microbiology/immunology and an M.B.A., all from the University of Rochester.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline is focused on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease and spinal muscular atrophy (SMA). Voyager has broad strategic collaborations with Genzyme Corporation, a Sanofi company, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities law. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the initiation, timing, progress and results of its preclinical programs and clinical trials and its research and development programs, its ability to advance its AAV-based gene therapies into, and successfully complete, clinical trials, its ability to continue to develop its product engine, its ability to add new programs to its pipeline, and the timing or likelihood of regulatory filings and approvals, are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s final prospectus for its initial public offering filed with the Securities and Exchange Commission, as updated by its future filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contact: Investor Relations: Sarah McCabe Stern Investor Relations, Inc. 212-362-1200 sarah@sternir.com Media: Katie Engleman Pure Communications, Inc. 910-509-3977 Katie@purecommunicationsinc.com
(ADAP) & (GSK) Expand Strategic Immunotherapy Collaboration
- Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trials
- Creates opportunity for up to eight combination studies
LONDON, PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T- cell receptor (TCR) engineered T-cell therapy to treat cancer, and GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) today announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer program, an affinity enhanced T-cell immunotherapy (GSK3377794) targeting NY-ESO-1, toward pivotal trials in synovial sarcoma.
Adaptimmune and GSK announced a strategic collaboration and licensing agreement in June 2014 for up to five programs, including the lead NY-ESO TCR program. GSK has an option on the NY-ESO-1 program through clinical proof of concept and, on exercise, will assume full responsibility for the program.
“We are delighted to broaden our collaboration with GSK, which is also fully committed to the development of this revolutionary T-cell therapy,” commented James Noble, Adaptimmune’s Chief Executive Officer. “We believe that our affinity enhanced T-cell programs have the potential to deliver important clinical benefit to cancer patients, and it is therefore essential that we accelerate our efforts to meet their needs. We are working closely with GSK to expedite development of our affinity enhanced T-cell therapy targeting NY-ESO, and if we succeed in generating pivotal data consistent with that of our ongoing studies, we believe it has the potential to be the first engineered T-cell therapy to reach the market.”
Dr. Axel Hoos, SVP Oncology R&D GSK said, “At GSK we’re progressing a pipeline of immuno-oncology therapies to stimulate anti-tumor immunity in patients. As we highlighted to investors at our R&D event last year, this Adaptimmune collaboration is a key element of that pipeline and is part of a comprehensive program for cell and gene therapy. With this expanded collaboration, we have the opportunity to accelerate the lead program in synovial sarcoma toward pivotal trials and also to investigate several other tumor types and combine the T-cell therapy with immune-modulating therapies such as checkpoint inhibitors.”
Under the terms of the expanded agreement, the companies will accelerate the development of Adaptimmune’s NY-ESO therapy into pivotal studies in synovial sarcoma and will explore development in myxoid round cell liposarcoma. Additionally, the companies may initiate up to eight proof-of-principle studies exploring combinations with other therapies, including checkpoint inhibitors.
According to the expanded development plan, the studies will be conducted by Adaptimmune with GSK effectively funding the pivotal studies and sharing the costs of the combination studies via a success based milestone structure.
Previous guidance relating to the collaboration disclosed potential cash payments to Adaptimmune of approximately $350m over the first 7 years from 2014 in relation to NY-ESO and two further programs. Given the changes announced today, and the advances made across the collaboration, Adaptimmune is updating and expanding this disclosure. Under the terms of the expanded agreement, the potential development milestones Adaptimmune is eligible to receive solely in relation to the NY-ESO program could amount to approximately $500 million, excluding previously received payments, if GSK exercises its option and successfully develops NY-ESO in more than one indication and more than one Human Leukocyte Antigen (HLA) type. In addition, Adaptimmune would receive tiered sales milestones and, as previously disclosed, mid-single to low double digit royalties on worldwide net sales. GSK has the right to nominate up to four additional targets in due course and Adaptimmune is eligible to receive further significant undisclosed milestone payments in relation to these earlier stage target programs.
Adaptimmune has also reiterated its prior cash burn guidance, which remains unchanged as the majority of the expansion and acceleration costs will be funded by GSK. For the full year 2016, the company expects its cash burn to be between $80 and $100 million, excluding cash burn associated with business development activities, and expects its cash position at December 31, 2016, including cash, cash equivalents, and short term deposits, to be at least $150 million.
About affinity enhanced T-cell candidates
Adaptimmune’s affinity enhanced T-cell candidates are novel cancer immunotherapies that have been engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response. Using its proprietary technology, Adaptimmune has created a pipeline of affinity enhanced T-cell therapies targeting certain antigens, including cancer testis antigens such as NY-ESO. NY-ESO-1 is one of the best-characterized and most immunogenic cancer testis antigens, and is frequently expressed by tumors of different origins and in advanced tumors. The company’s trials in the NY-ESO-1 program in multiple myeloma, melanoma, sarcoma and ovarian cancer continue to generate encouraging results.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D ‘Risk factors’ in the company’s Annual Report on Form 20-F for 2014.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 20-F filed with the Securities and Exchange Commission on October 13, 2015. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: will.roberts@adaptimmune.com Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: margaret.henry@adaptimmune.com
(HNSN) Announces FDA Clearance of the Magellan(TM) Robotic Catheter eKit
MOUNTAIN VIEW, CA–(Feb 2, 2016) – Hansen Medical®, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the Magellan™ Robotic Catheter eKit (MRC eKit). The MRC eKit is the company’s latest addition to the family of approved Magellan Robotic Catheters and helps extend robotic capabilities and control throughout procedures in the peripheral vasculature. With the MRC eKit, physicians will now have robotic control of 3rd party microcatheters through the existing Magellan Robotic Catheter 6Fr architecture. This added ability has the potential to help reduce procedure times and radiation exposure.
This approval comes after multiple cases were performed with the MRC eKit by Professor Marc Sapoval, MD, MSc at Hôpital Européen Georges Pompidou (HEGP-APHP) in Paris, France as a part of the Embolization Procedures in Peripheral Vasculature clinical study. Professor Sapoval successfully performed several prostate artery embolization (PAE) procedures and uterine artery embolization (UFE) procedures with the MRC eKit as a part of this study.
With FDA approval, the MRC eKit will now be used by physicians in the United States. “The new Magellan Robotic Catheter eKit is a big step forward for our robotic vascular procedures,” said Ripal Gandhi, MD of Miami Cardiac & Vascular Institute (MCVI) in Miami, FL. “With the added robotic capabilities, we will be able to work outside of the radiation zone throughout more of the procedure and will be able to extend the stability and precision of robotic technology to the smaller microcatheters during our procedures.”
“We are proud to continue to offer advances in our portfolio of robotic catheters,” said Cary Vance, Chief Executive Officer of Hansen Medical. “We have seen strong robotic procedure growth, particularly in men’s health, women’s health and cancer treatment, since the introduction of the Magellan Robotic Catheter 6Fr, and we expect that the development of the Magellan Robotic Catheter eKit will continue to expand our presence within the Interventional Radiology space. We have placed a heavy focus on advancing our Magellan technology to enable robotic control of smaller catheters and look forward to the benefits that these added robotic capabilities will offer to patients and physicians.”
The Magellan Robotic System is an advanced technology that drives Magellan Robotic Catheters and guide wires during minimally-invasive, endovascular procedures. Magellan is designed to offer procedural predictability, precision, and catheter stability as physicians navigate inside blood vessels and deliver therapy. Image-guided medical procedures using interventional fluoroscopy, while growing rapidly, are the leading source of occupational ionizing radiation exposure for medical personnel1. Magellan’s remote workstation allows physicians to control robotic catheters and guide wires while seated away from the radiation field, which has been shown to reduce radiation exposure for the physician by as much as 95% in complex endovascular procedures2.
About the Magellan™ Robotic System
Hansen Medical’s Magellan Robotic System is intended to be used to facilitate navigation in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan Robotic System is designed to deliver predictability, control and catheter stability to endovascular procedures. Since its commercial introduction in the U.S. and Europe, the Magellan Robotic System has demonstrated its clinical versatility in many cases in a broad variety of peripheral vascular procedures globally. The Magellan Robotic Catheter eKit provides robotic control of 3rd party microcatheters through a robotic catheter with dual-bend technology. It is intended to be used to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices and is intended to be used with the Hansen Medical Magellan Robotic System and accessories.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company’s Magellan™ Robotic System, Magellan Robotic Catheters, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company’s mission is to enable cardiac arrhythmia and endovascular procedures and to improve patient outcomes through the use of intravascular robotics. Additional information can be found at www.hansenmedical.com.
“Hansen Medical,” “Hansen Medical (with Heart Design),” and “Heart Design (Logo)” are registered trademarks, and “Magellan” and “Hansen Medical Magellan” are trademarks of Hansen Medical, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “potential,” “believes,” “goal,” “estimate,” “anticipates,” and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2014, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
1 U.S. Environmental Protection Agency of Radiation Protection Programs Home Page; Health Effects, http://www.epa.gov/rpdweb00/understand/health_effects.html (Accessed on November 10, 2014)
2 Robotic Catheter Assistance: The Relationship on Radiation Exposure, presentation by Barry Katzen, MD during Charing Cross International Symposium, London, April 29, 2015.
(AVXL) to Present at 18th Annual BIO CEO & Investor Conference on February 9th 2016
NEW YORK, Feb. 02, 2016 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference.
Dr. Missling’s presentation is scheduled to take place on Tuesday, February 9, 2016 at 1:30 p.m. ET at the Waldorf-Astoria Hotel, Conrad Suite, in New York, NY. Investors may view Dr. Missling’s presentation via live webcast (http://www.veracast.com/webcasts/bio/ceoinvestor2016/85223495157.cfm) or access an archived version via Anavex.com.
The 18th Annual BIO CEO & Investor Conference is hosted by the Biotechnology Industry Organization. It is the largest independent investor conference focused on established and emerging publicly traded and select private biotech companies.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer’s disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in convulsive epileptic animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: ir@anavex.com www.anavex.com
(COYN) COPsync911™ Implemented at Nichols College
Nichols is First College in Massachusetts to Use the Threat-Alert Protection System
DALLAS, Feb. 02, 2016 — COPsync, Inc. (NASDAQ:COYN), which operates the nation’s largest law enforcement real-time, in-car information sharing, communication and data interoperability network, announced today that Nichols College in Dudley, Mass., will be the first college in Massachusetts to implement the COPsync911 threat-alert system.
While the threat-alert system has already been implemented in several on-campus buildings, Nichols is expanding the installation to include a number of new on-campus buildings.
Nichols College is now part of an increasing number of municipalities that have joined the COPsync911 network as the system continues to be adopted across the nation. The COPsync911 system is activated by school faculty and staff when a threatening situation arises, and allows the employees to send an immediate and silent alert to all other employees, the local law enforcement dispatch center, all patrol cars and on-duty law enforcement officers, even if they are away from their patrol car.
Ronald A. Woessner, CEO of COPsync said, “We are excited to welcome our first college campus in Massachusetts to the COPsync911 threat-alert system as we move forward with the nationwide rollout of this important service. Nichols College is a thought leader in the area of school safety, and its adoption of COPsync911 paves the way for further expansion throughout New England. The College now joins the growing family of municipalities in the northeastern United States — including Maine, New Hampshire, Massachusetts, and Rhode Island — that are part of the COPsync911 network and have prioritized the safety of their students, staff, and faculty.”
Nichols College Chief Information Officer Kevin Brassard said: “Ensuring the safety of Nichols College’s student body of over 1,200 students requires a concerted and coordinated effort among law enforcement and college staff and faculty. We have implemented a multi-pronged approach to the safety of our campus that includes the COPsync911 threat-alert system. We are proud to provide an environment where our students can thrive as learners, thinkers, and citizens.”
About COPsync, Inc.
COPsync, Inc. (COYN) is a technology company that improves communication between and among law enforcement officers and agencies from differing jurisdictions to help them prevent and respond more quickly to crime. The COPsync Network™ connects law enforcement officers and agencies to a common communications system, which gives officers instant access to actionable, mission-critical data and enables them to share information and communicate in real-time with other officers and agencies, even those hundreds and thousands of miles away. The Network’s companion, COPsync911™ threat-alert system, enables schools, courts, hospitals, government buildings, energy, telecommunications and other potentially at-risk facilities to automatically and silently send threat-alerts directly to local law enforcement officers in their patrol cars in the event of a crisis, thereby speeding first responder response times and saving minutes when seconds count. The COPsync Network saves officer and citizen lives, reduces unsolved crimes and assists in apprehending criminals and interdicting criminal behavior — through such features as a nationwide officer safety alert system, GPS/auto vehicle location and distance-based alerts for crimes in progress, such as school crisis situations, child abductions, bank robberies and police pursuits. The COPsync Network also eliminates manual processes and increases officer productivity by enabling officers to write electronic tickets, accident reports, DUI forms, arrest forms and incident and offense reports. The company also sells VidTac®, an in-vehicle, software-driven video system for law enforcement. Visit www.copsync.com and www.copsync911.com for more information.
About Nichols College
Nichols College is a college of choice for business and leadership education as a result of its distinctive career-focused and leadership-based approaches to learning, both in and out of the classroom. Founded in 1815, Nichols transforms today’s students into tomorrow’s leaders through a dynamic, career-focused business and professional education. Nichols serves students interested primarily in a comprehensive business education that is supported by a strong liberal arts curriculum. For more information about Nichols College, please visit www.nichols.edu.
Contacts For COPsync: Ronald A. Woessner Chief Executive Officer 972-865-6192 invest@copsync.com Media: Fred Sommer Senior Consultant Investor Relations Ascendant Partners, LLC. 732-410-9810 fred@ascendantpartnersllc.com College: Lorraine U. Martinelle Director of Public Relations Nichols College Dudley, Mass. 508-213-2219 Lorraine.martinelle@nichols.edu
(MGI) and Walmart Announce New Three-Year Agreement
All MoneyGram services to continue at more than 4,000 Walmart locations
DALLAS, Feb. 1, 2016 — MoneyGram (NASDAQ: MGI) announced today the extension of their more than 17-year relationship with Walmart. This new three-year agreement, which begins on Feb. 1, continues MoneyGram’s domestic and international money transfer service as well as its bill pay and money order products at Walmart’s more than 4,000 locations in the U.S. and Puerto Rico. Walmart customers can also continue to access MoneyGram services through Walmart.com to send and receive money.
“We are extremely pleased to extend our relationship with Walmart for an additional three years,” said Alex Holmes, MoneyGram CEO. “For nearly two decades now, MoneyGram and Walmart have worked side by side to make money transfers and other financial services affordable and convenient for our customers.”
“Leveraging our size and scale to take on big challenges and create better ways to serve our customers is something we’re always working on. MoneyGram is a great provider in helping us deliver results that matter to our customers, offering innovative products and services that help them better manage their finances for less,” said Kirsty Ward, Walmart Senior Director, U.S. Financial Services.
Walmart and MoneyGram are committed to ongoing innovation in order to meet the evolving needs of the customer. Both companies will continue to make investments in marketing, technology and product development, including the roll-out of a redesigned online experience.
“MoneyGram is committed to fully understanding the expectations of our customers and agents and to enhancing their money transfer experience,” said Holmes. “This is a very dynamic industry and we are constantly looking to offer our customers new and better ways to send and receive money.”
#moneygramnews
About MoneyGram International, Inc.
MoneyGram is a global provider of innovative money transfer and payment services and is recognized worldwide as a financial connection to friends and family. Whether online, or through a mobile device, at a kiosk or in a local store, we connect consumers any way that is convenient for them. We also provide bill payment services, issue money orders and process official checks in select markets. More information about MoneyGram International, Inc. is available at moneygram.com.
Forward-Looking Statements
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to, among other things, the financial condition, results of operations, plans, objectives, future performance and business of MoneyGram and its subsidiaries. Forward-looking statements can be identified by words such as “believes,” “estimates,” “expects,” “projects,” “plans,” “intends,” “continues,” “will,” “should,” “could,” “would,” “may,” “goals,” “anticipates” and other similar expressions. These forward-looking statements speak only as of the date they are made, and MoneyGram undertakes no obligation to publicly update or revise any forward-looking statement for any reason, whether as a result of new information, future events or otherwise, except as required by federal securities law. These forward-looking statements are based on management’s current expectations, beliefs and assumptions and are subject to certain risks, uncertainties and changes in circumstances due to a number of factors. These factors include, but are not limited to: our ability to compete effectively; our ability to maintain key agent or biller relationships, or a reduction in business or transaction volume from these relationships, including our largest agent, Walmart, through the introduction by Walmart of a competing “white label” branded money transfer product or otherwise; the impact of our U.S.-to-U.S. pricing strategy; our ability to manage fraud risks from consumers or agents; the ability of us and our agents to comply with U.S. and international laws and regulations; litigation or regulatory proceedings involving us or our agents, including the outcome of ongoing investigations by several state governments, which could result in material settlements, fines or penalties, revocation of required licenses or registrations, terminations of contracts, other administrative actions or lawsuits and negative publicity; possible uncertainties relating to compliance with and the impact of the deferred prosecution agreement entered into with the U.S. federal government and the effect of the deferred prosecution agreement on our reputation and business; current or proposed regulations addressing consumer privacy and data use and security; our ability to successfully develop and timely introduce new and enhanced products and services and our investments in new products, services or infrastructure changes; our offering of money transfer services through agents in regions that are politically volatile or, in a limited number of cases, that are subject to certain Office of Foreign Assets Control restrictions; changes in tax laws or an unfavorable outcome with respect to the audit of our tax returns or tax positions, or a failure by us to establish adequate reserves for tax events; our substantial debt service obligations, significant debt covenant requirements and credit rating and our ability to maintain sufficient capital; our ability to manage risks associated with our international sales and operations; major bank failure or sustained financial market illiquidity, or illiquidity at our clearing, cash management and custodial financial institutions; the ability of us and our agents to maintain adequate banking relationships; a security or privacy breach in systems, networks or databases on which we rely; disruptions to our computer systems and data centers and our ability to effectively operate and adapt our technology; weakened consumer confidence in our business or money transfers generally; continued weakness in economic conditions, in both the U.S. and global markets; a significant change, material slow down or complete disruption of international migration patterns; the financial health of certain European countries, and the impact that those countries may have on the sustainability of the euro; our ability to manage credit risks from our retail agents and official check financial institution customers; our ability to retain partners to operate our official check and money order businesses; our ability to adequately protect our brand and intellectual property rights and to avoid infringing on the rights of others; our ability to attract and retain key employees; our ability to manage risks related to the operation of retail locations and the acquisition or start-up of businesses; any restructuring actions and cost reduction initiatives that we undertake may not deliver the expected results and these actions may adversely affect our business; our ability to maintain effective internal controls; our capital structure and the special voting rights provided to designees of Thomas H. Lee Partners, L.P. on our Board of Directors; and the risks and uncertainties described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of MoneyGram’s annual report on Form 10-K for the year ended December 31, 2014 and subsequent Forms 10-Q, as well as any additional risk factors that may be described in MoneyGram’s other filings with the Securities and Exchange Commission from time to time.
(CAMP) to Acquire (LOJN)
Combination Creates Leader in Connected Car Solutions and Vehicle Telematics Applications With More Than $400 Million in Annual Revenue Expected in Fiscal 2017 Expected to Be Accretive to CalAmp Non-GAAP Earnings per Share by $0.15 to $0.25 in First 12 Months Transaction Value of Approximately $134 Million
OXNARD, CA and CANTON, MA–(Feb 1, 2016) – CalAmp (NASDAQ: CAMP), a leading provider of wireless products, services and solutions, and LoJack Corporation (NASDAQ: LOJN) (“LoJack”), a provider of vehicle theft recovery systems and advanced fleet management solutions, today announced that the companies have entered into a definitive agreement pursuant to which CalAmp will acquire all of the outstanding shares of common stock of LoJack for $6.45 per share in an all cash transaction valued at approximately $134 million.
This transaction, which has been unanimously approved by both companies’ Boards of Directors, will create a leader in connected car solutions and vehicle telematics applications. The combination builds on both companies’ complementary strengths and is expected to accelerate the broad adoption of vehicle telematics technologies and applications around the globe.
“The acquisition of LoJack aligns with our strategy to deliver innovative, next generation connected vehicle telematics technologies, thereby accelerating our roadmap in these large and fast growing markets, while creating value for our customers, partners and shareholders,” said Michael Burdiek, CalAmp’s President and Chief Executive Officer. “By combining with LoJack, we expect to enhance our ability to deliver novel connected vehicle telematics technologies and applications to our global customers. Moreover, we believe that LoJack’s considerable relationships, particularly in the U.S. auto dealer channel, as well as in the commercial space with heavy equipment providers and their international licensee footprint, will create new opportunities for growth and strengthen our competitive position. We are excited to welcome LoJack’s talented team to CalAmp and look forward to realizing the benefits that we expect this transaction to create.”
“This transaction delivers immediate and significant cash value to our shareholders at a substantial premium and represents a successful conclusion to the Board’s review of strategic alternatives to enhance shareholder value,” said Randy Ortiz, LoJack’s President and Chief Executive Officer. “We are proud that CalAmp recognizes LoJack’s success over the last 30 years in creating best-in-class theft recovery solutions and developing strong channel and end customer relationships around the world. With CalAmp as our partner, the LoJack brand will continue to expand beyond our foundational stolen vehicle recovery business by providing our customers and partners with enhanced product offerings to better protect and manage their assets. We look forward to working with the CalAmp team to ensure a smooth transition and accelerate the strategic initiatives already underway at LoJack as we take our great brand into the future.”
Anticipated Strategic and Financial Benefits of Transaction
- Creates market leader well-positioned to succeed through powerful combination of best-in-class products with broad market access: CalAmp’s leading portfolio of wireless connectivity devices, software, services and applications, combined with LoJack’s world renowned brand, proprietary stolen vehicle recovery product, unique law enforcement network and strong relationships with auto dealers, heavy equipment providers and global licensees, will create a market leader that is well-positioned to drive the broad adoption of connected car solutions and vehicle telematics technologies and applications worldwide.
- Provides customers and industry participants in target markets with exciting value proposition: The combined company will offer customers access to integrated, turnkey offerings that enable a multitude of high value applications encompassing vehicle security and enhanced driver safety. Furthermore, the combination of CalAmp’s and LoJack’s technology offerings is expected to provide global customers with connected vehicle applications to help ensure that retail auto dealers remain competitive and relevant in today’s rapidly evolving markets.
- Accretive transaction and updated business outlook: The transaction is expected to be highly accretive to CalAmp’s earnings in the first 12 months following consummation of the transaction. Based on the estimated timeframe for closing, CalAmp expects consolidated revenue to be in excess of $400 million for its fiscal year ending February 28, 2017, and for LoJack to contribute approximately $10 million in Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, stock compensation expense and acquisition-related expenses) and $0.15 to $0.25 in Non-GAAP earnings per share to CalAmp’s fiscal 2017 consolidated results. CalAmp’s Non-GAAP earnings per share exclude intangibles amortization, stock compensation expense, acquisition-related expenses, and non-cash income tax expense.
Closing and Approvals
Under the terms of the definitive agreement, a wholly-owned subsidiary of CalAmp will commence a tender offer to acquire all of the outstanding shares of LoJack common stock for $6.45 per share of LoJack common stock tendered. Following completion of the tender offer, the parties will effect a second-step merger pursuant to which all remaining shares of LoJack common stock not tendered in the offer will be converted into the right to receive the same cash price per share as in the offer. The transaction is expected to close during CalAmp’s fiscal 2017 first quarter, subject to customary closing conditions, including regulatory approvals and the tender of a number of LoJack shares that, together with other shares owned or to be acquired by CalAmp and its subsidiaries, represent at least two thirds of the total number of LoJack’s outstanding shares. CalAmp will fund the acquisition with existing cash on hand.
Advisors
Canaccord Genuity is serving as financial advisor to CalAmp, and Gibson, Dunn & Crutcher LLP is serving as its legal counsel. Pacific Crest Securities, a division of KeyBanc Capital Markets Inc., is serving as financial advisor to LoJack, and Goodwin Procter LLP is serving as its legal counsel.
About CalAmp
CalAmp (NASDAQ: CAMP) is a proven leader in providing wireless communications solutions to a broad array of vertical market applications and customers. CalAmp’s extensive portfolio of intelligent communications devices, robust and scalable cloud service platform, and targeted software applications streamline otherwise complex Machine-to-Machine (M2M) deployments. These solutions enable customers to optimize their operations by collecting, monitoring and efficiently reporting business critical data and desired intelligence from high-value mobile and remote assets. For more information, please visit www.calamp.com.
About LoJack Corporation
LoJack Corporation, the company that has helped more than nine million people protect their vehicles in the event of theft over the past 25+ years, today provides safety, security and protection for an ever-growing range of valuable assets and people. Leveraging its core strengths, including its well-known brand, direct integration with law enforcement and dealer distribution network, LoJack Corporation is expanding our business to include our traditional vehicle and equipment theft recovery, people at risk and new telematics-based products and services. LoJack is delivering new telematics-based solutions for on-road and off-road fleet management, as well as dealer inventory management. By expanding our brand beyond stolen vehicle recovery, LoJack Corporation is committed to creating a new level of value for its dealer, licensee, customer and investor communities by delivering innovative offerings and multiple technologies in expanding geographies. For more information, visit www.lojack.com.
Forward-Looking Statements
This release contains forward-looking statements related to the proposed transaction and business combination between CalAmp and LoJack, including statements regarding the benefits and timing of the transaction, as well as statements regarding the companies’ products, markets and growth opportunities. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including the following, among others: the minimum percentage of tendered shares in the tender offer necessary to complete the offer or the second-step merger promptly following the offer; closing of the transaction may not occur or may be delayed; expected synergies and other financial benefits of the transaction may not be realized; integration of the acquisition post-closing may not occur as anticipated; litigation or alternative dispute resolution related to the transaction or limitations or restrictions imposed by regulatory authorities may delay or negatively impact the transaction; the pendency of the transaction may result in disruptions to LoJack’s business and make it more difficult to maintain relationships with employees, customers, vendors and other business partners; delays, disruptions or increased costs in the integration of LoJack’s technology in existing or new products may arise; unanticipated restructuring costs may be incurred; attempts to retain key personnel and customers may not succeed; the business combination or the combined companies’ products may not be supported by third parties; actions by competitors may negatively impact results; and there may be negative changes in general economic conditions in the regions or the industries in which CalAmp and LoJack operate. In addition, please refer to the documents that CalAmp and LoJack file with the Securities and Exchange Commission (“SEC”) on Forms 10-K, 10-Q, and 8-K, including the specific risk factors included in such filings. These filings identify and address other important risks and uncertainties that could cause events and results to differ materially from those contained in the forward-looking statements set forth in this release. Readers are cautioned not to put undue reliance on these forward-looking statements, and CalAmp and LoJack assume no obligation to update, and do not intend to update, these forward-looking statements, whether as a result of new information, future events or otherwise.
Important Additional Information
This release relates to a pending business combination transaction between CalAmp and LoJack. The tender offer referenced in this release has not yet commenced. No statement in this release constitutes an offer to buy, or the solicitation of an offer to sell, any securities. A solicitation and an offer to buy shares of LoJack will be made only pursuant to an offer to purchase and related materials that CalAmp intends to file with the SEC. When the tender offer is commenced, CalAmp will file a Tender Offer Statement on Schedule TO related to the transaction with the SEC and may file amendments thereto, and thereafter LoJack will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. CalAmp and LoJack may also file other documents with the SEC regarding the transaction. This document is not a substitute for Schedule TO, the Schedule 14D-9 or any other document that CalAmp or LoJack may file with the SEC in connection with the transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE SCHEDULE TO (INCLUDING THE OFFER TO PURCHASE, THE RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS), THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 AND THE OTHER RELEVANT MATERIALS WITH RESPECT TO THE TRANSACTION CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BEFORE MAKING ANY INVESTMENT DECISION WITH RESPECT TO THE TRANSACTION, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
The Tender Offer Statement and Solicitation/Recommendation Statement on Schedule 14D-9 (when available) will be sent free of charge to LoJack’s shareholders. Such materials (and all other offer documents filed with the SEC) will be available at no charge on the SEC’s Web site: www.sec.gov or by directing such requests to the Information Agent for the tender offer who will be named in the Tender Offer Statement. In addition, copies of LoJack’s filings with the SEC may also be obtained free of charge at the “Investor Relations” section of LoJack’s website at www.lojack.com
AT CALAMP:
Garo Sarkissian
SVP, Corporate Development
(805) 987-9000
AT ADDO COMMUNICATIONS:
Lasse Glassen
General Information
(424) 238-6249
Email Contact
AT JOELE FRANK, WILKINSON BRIMMER KATCHER:
Eric Brielmann or Arielle Rothstein
(415) 869-3950
or
Dan Katcher or Joseph Sala
(212) 355-4449
AT LOJACK:
Ken Dumas
SVP, CFO & Treasurer
(781) 302-4322
(AYA) Confirms Non-Binding Indication from CEO on All-Cash Acquisition
MONTREAL, Feb. 1, 2016 – Amaya Inc. (NASDAQ: AYA; TSX: AYA) confirmed today that it has received a non-binding indication from its Chairman and Chief Executive Officer, David Baazov, that he intends to make an all-cash proposal to acquire Amaya at a price currently estimated by Mr. Baazov to be C$21.00 per common share. The board of directors of Amaya has established a special committee of independent directors to review any proposal that may be forthcoming, as well as other alternatives that may become available to Amaya. Amaya’s Lead Independent Director, Dave Gadhia, will chair the special committee.
As of the time of this release, the special committee has neither received nor solicited a formal bid or offer related to a potential transaction and there can be no assurance that Mr. Baazov’s intention will result in a formal bid or offer or that any such bid or offer will ultimately result in a completed transaction.
Shareholders of Amaya do not need to take any action with respect to any potential proposal at this time. Amaya intends to provide updates if and when necessary in accordance with applicable securities laws.
About Amaya
Amaya is a leading provider of technology-based products and services in the global gaming and interactive entertainment industries. Amaya owns gaming and related consumer businesses and brands including PokerStars, Full Tilt, BetStars, StarsDraft, the European Poker Tour, PokerStars Caribbean Adventure, Latin American Poker Tour and the Asia Pacific Poker Tour. These brands have more than 97 million cumulative registered customers globally and collectively form the largest poker business in the world, comprising online poker games and tournaments, live poker competitions, branded poker rooms in popular casinos in major cities around the world, and poker programming created for television and online audiences. Amaya, through certain of these brands, also offers non-poker gaming products, including casino, sportsbook and daily fantasy sports. Amaya has various gaming and gaming-related licenses or approvals throughout the world, including from the United Kingdom, Italy, France, Spain, Estonia, Belgium, Denmark, Bulgaria, Greece, Ireland, Romania, the Isle of Man, Malta, the State of Schleswig-Holstein in Germany, the Province of Quebec in Canada, and the State of New Jersey in the United States.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable securities laws, including, without limitation, the intentions of Amaya’s Chief Executive Officer and certain potential future transactions. Forward-looking statements can, but may not always, be identified by the use of words such as “anticipate”, “propose”, “plan”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “predict”, “potential”, “targeting”, “intend”, “could”, “might”, “would”, “should”, “believe”, “objective”, “ongoing” and similar references to future periods or the negatives of these words and expressions. These statements, other than statements of historical fact, are based on management’s current expectations and are subject to a number of risks, uncertainties, and assumptions, including market and economic conditions, business prospects or opportunities, future plans and strategies, projections, technological developments, anticipated events and trends and regulatory changes that affect us, our customers and our industries. Although Amaya and management believe the expectations reflected in such forward-looking statements are reasonable and are based on reasonable assumptions and estimates, there can be no assurance that these assumptions or estimates are accurate or that any of these expectations will prove accurate. Forward-looking statements are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that could cause actual events to differ materially from those expressed or implied in such statements. Applicable risks and uncertainties include, but are not limited to, those identified under the heading “Risk Factors and Uncertainties” in Amaya’s Annual Information Form for the year ended December 31, 2014 and in its Management’s Discussion and Analysis for the period ended September 30, 2015, each available on SEDAR at www.sedar.com, EDGAR at www.sec.gov and Amaya’s website at www.amaya.com, and in other filings that Amaya has made and may make with applicable securities authorities in the future. Investors are cautioned not to put undue reliance on forward-looking statements. Any forward-looking statement speaks only as of the date hereof, and Amaya undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
(HNSN) Latest Publication in Journal of Interventional Cardiac Electrophysiology
Analysis of Catheter Contact Force During Atrial Fibrillation Ablation Using the Robotic Navigation System: Results From a Randomized Study
MOUNTAIN VIEW, CA–(Feb 1, 2016) – Hansen Medical, Inc. (NASDAQ: HNSN), the global leader in intravascular robotics, today announced the latest publication in the Journal of Cardiac Electrophysiology: Analysis of catheter contact force during atrial fibrillation ablation, using the robotic navigation system: results from a randomized study.
The purpose of this study, led by Dr. Antonio Dello Russo and Dr. Claudio Tondo of the Cardiac Arrhythmia Research Center, Centro Cardiologico Monzino in Milan, Italy, was to evaluate catheter contact force (CF) measurements both with and without the use of Sensei® X robotic navigation system (RNS) during pulmonary vein isolation (PVI) procedures. The study evaluated eighty patients with symptomatic atrial fibrillation (AF). Fifty-seven patients had paroxysmal AF and 23 early persistent AF. All procedures were performed with the Thermocool® SmartTouch™ ablation catheter.
Atrial fibrillation ablation was performed successfully in all patients without complications, CF and the 1-year freedom from AF recurrence was higher in the RNS group while this same group was observed to have a significant reduction in fluoroscopy time (13 ± 10 vs. 20 ± 10 min, respectively, p = 0.05).
Dr. Joe Gallinghouse, M.D., Cardiac Electrophysiologist at St. David’s Medical Center in Austin, Texas and Principal Investigator of the ARTISAN AF IDE Study previously stated, “There is a substantial amount of innovation in the treatment of atrial fibrillation for catheter ablation, including distal tip contact force sensing catheters like SmartTouch. Early studies have indicated that the combination of SmartTouch and Sensei robotic navigation could provide improved outcomes for patients.” The company recently completed enrollment in the ARTISAN AF IDE Study designed to support the expansion of the company’s current labeling in the U.S. beyond mapping.
The research from Cardiologico Monzino in Milan, Italy continues to support the quality of the ablation lesions based on a combination of the contact between the catheter tip and heart wall, the power of the applied radiofrequency energy, and the amount of time the energy is applied. The stability and control of the Sensei system improves the contact between the catheter tip and heart wall1. The EnSite Velocity Mapping System facilitates 3D navigation of catheters in the heart atria. Sensei’s CoHesion feature offers physicians excellent catheter control by integrating the EnSite Velocity 3D map into the navigation function of Sensei’s physician workstation.
“The Sensei Robotic System is a key technology which enables electrophysiology procedures. The results from the team at Cardiologico Monzino in Milan prove the need for this critical technology,” said Cary Vance, Hansen Medical President and CEO. “By continuing to innovate technologies, more and more physicians have the ability to achieve these types of results, ultimately providing the patients with perfected outcomes.”
Cardiac arrhythmias are abnormal electrical signals in the heart. Atrial fibrillation is the most common form of cardiac arrhythmia, affecting nearly 3 million people in the United States alone2. In radiofrequency catheter ablation, a catheter is inserted into left atrium and radiofrequency energy is delivered to the heart tissue to create scars, which are intended to block erratic electrical impulses so the left atrium can beat normally.
About the Sensei® Robotic System
The Sensei Robotic System combines advanced levels of 3D catheter control and 3D visualization. This unique, state of the art technology has been used in thousands of patients, and is powered by a robotically controlled arm that allows for catheter navigation, stability and positioning within the patient’s heart atria. The Sensei Robotic System, control catheters and accessories are intended to facilitate manipulation, positioning and control of Hansen Medical’s robotically steerable catheters for collecting electrophysiological data within the heart atria with electro-anatomic mapping and recording systems, using specified percutaneous mapping catheters. The Sensei Robotic System is powered by a robotically controlled arm that allows for catheter navigation and stability. The safety and effectiveness of this device for use with cardiac ablation catheters, in the treatment of cardiac arrhythmias including atrial fibrillation, have not been established.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in Intravascular Robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company’s Magellan™ Robotic System, Magellan Robotic Catheters, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Company’s mission is to enable cardiac arrhythmia and endovascular procedures and to improve patient outcomes through the use of intravascular robotics. Additional information can be found at www.hansenmedical.com.
“Hansen Medical,” “Hansen Medical (with Heart Design),” and “Heart Design (Logo)” are registered trademarks, and “Magellan” and “Hansen Medical Magellan” are trademarks of Hansen Medical, Inc. in the U.S. and other countries. All other trademarks are the property of their respective owners.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words “plan,” “expects,” “potential,” “believes,” “goal,” “estimate,” “anticipates,” and other similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements regarding the potential benefits of our robotic systems for hospitals, patients and physicians. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: factors relating to engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the rate of adoption of our systems and the rate of use of our catheters; our ability to manage expenses and cash flow, and obtain adequate financing; and other risks more fully described in the “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2014, as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
(CBMX) Study Published in Genetics in Medicine
Study Supports Follow-up Diagnostic Testing to Confirm Positive Results From Non-invasive Prenatal Testing
IRVINE, Calif., Feb. 01, 2016 — CombiMatrix Corporation (NASDAQ:CBMX), a molecular diagnostics company specializing in DNA-based testing services for prenatal and postnatal developmental disorders and pre-implantation genetic screening services, announces the publication of data from a CombiMatrix study supporting the value of follow-up diagnostic testing to either confirm or rule out positive results for common chromosomal aneuploidies and microdeletion syndromes detected by non-invasive prenatal testing (NIPT).
The data from the study appeared in the peer-reviewed Genetics in Medicine advance online publication (21 January 2016. doi:10.1038/gim.2015.196) submitted by Trilochan Sahoo, M.D., FACMG, CombiMatrix’s Vice President of Clinical Affairs and Director of Cytogenetics, in a letter to the editor entitled, “Expanding non-invasive prenatal testing to include microdeletions and segmental aneuploidy: cause for concern?” The letter provides “important and substantial addition” to the conclusion in a previously published article in Genetics in Medicine, “Maternal cell-free DNA-based screening for fetal microdeletion and the importance of careful diagnostic follow-up,” Yatsenko SA, et. al.
“Our study supports the need for extreme caution in the interpretation of NIPT due to higher-than-previously reported false positive rates compared with invasive testing and concern regarding the potential of over-representation of the positive predictive value for specific aneuploidies and microdeletions,” said Dr. Sahoo. Common chromosomal fetal aneuploidies include Down (trisomy 21), Edwards (trisomy 18) and Patau (trisomy 13) syndromes, and common microdeletion syndromes are associated with conditions such as intellectual disability, seizures, autism spectrum disorder and neuropsychiatric disorder.
The CombiMatrix study included a review of the results of chromosomal microarrays and/or karyotype analysis following NIPT on 277 evaluable cases, showing a discordance rate of 20% and partial discordance rate of 11%. The study included 25 cases in which NIPT showed a microdeletion or segmentation fetal aneuploidy. The conclusion drawn in the Yatsenko, et. al, article was based on the observation of a single microdeletion case.
“The most significant and recent observation from our study showed a high rate of false positives for microdeletions,” continued Dr. Sahoo. “This makes it extremely prudent to take a much more cautious approach to expanding NIPT for microdeletions with definitive testing such that we offer at CombiMatrix.” Dr. Sahoo presented data from this study at the American Society of Human Genetics in October 2015.
“Major providers of NIPT are expanding beyond screening for common chromosomal fetal aneuploidies to common microdeletion syndrome and the results of these tests can lead to important decisions for women and their families,” said Mark McDonough, President and Chief Executive Officer of CombiMatrix. “We recommend extensive pretest genetic counseling with a complete discussion of the benefits and limitations of screening versus diagnostic testing. This is particularly important for patients determined as low-risk for abnormalities in which abnormalities are detected with NIPT and for patients considered high-risk with normal NIPT results.”
Highlights of the 25 cases in which the CombiMatrix study compared NIPT results indicating aneuploidy and microdeletions with microarray and/or karyotyping results included:
- Discordance in 5 out of 7 cases with deletion 22q11.21; 5 out of 6 cases with deletion 5p; 3 out of 4 cases with deletion 1p36; and 1 out of 1 case with deletion 4p.
- Concordance in 1 case each identifying 15q deletion, a 9p duplication [confirmed to be an isodicentric (9p)] and a 13q deletion.
- Partial concordance in single cases as follows:
- NIPT was suggestive of both 18p and 18q terminal deletions, diagnostic testing revealed only a deletion of 14 Mb at 18p11.32p11.21.
- NIPT suggestive of trisomy 18q, diagnostic testing showed a duplication of 18p11.21q23 that was further characterized to be a translocation of the duplicated segment to the p-arm of one chromosome 13, resulting in trisomy for the 18p11.21q23 segment.
- NIPT results indicated a “partial deletion of 21q,” diagnostic testing revealed a duplication of 9.2 Mb at 21q11.2-q21.1 that was inserted at 14p11.2.
- NIPT results were inconclusive for chromosome 13, microarray testing showed a large region of allelic homozygosity for chromosome 13.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in prenatal diagnostics, miscarriage analysis for recurrent pregnancy loss, pediatric genetics and pre-implantation genetic screening, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations, speak only as of the date hereof and are subject to change. All statements, other than statements of historical fact included in this press release, are forward-looking statements. Forward-looking statements can often be identified by words such as “anticipates,” “expects,” “intends,” “plans,” “goal,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions, and variations or negatives of these words and include, but are not limited to, statements regarding projected results of operations and management’s future business, operational and strategic plans, recruiting efforts and test menu expansion. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. The risks and uncertainties referred to above include, but are not limited to: whether follow-up diagnostic testing is more reliable than NIPT; whether the CombiMatrix study contains errors or could be contradicted or disproven by other studies; our ability to successfully expand the base of our customers and strategic partners, add to the menu of our diagnostic tests, develop and introduce new tests and related reports, expand and improve our current suite of services, optimize the reimbursements received for our microarray testing services, and increase operating margins by improving overall productivity and expanding sales volumes; our ability to successfully accelerate sales, steadily increase the size of our customer rosters in both prenatal and developmental genetic testing markets; our ability to attract and retain a qualified sales force in wider geographies; our ability to ramp production from our sales force and our strategic partners; rapid technological change in our markets; changes in demand for our future services; legislative, regulatory and competitive developments; the outcome of pending litigation; general economic conditions; and various other factors. Further information on potential factors that could affect our financial results is included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, except as required by law.
Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation (949) 753-0624 Investor Relations Contact: LHA Jody Cain (310) 691-7100 jcain@lhai.com
(OPCO) Commits to Further Innovation in Pet Products
New Partnership With Global Leader Aplix Underscores Strategic Commitment
FAIRPORT HARBOR, OH–(February 01, 2016) – Exemplifying OurPet’s Company’s (OTCQX: OPCO) historical commitment to the development of products designed to enhance the bond between pets and humans, the company today announces its strategic partnership with Aplix IP Holdings Corp., a Japan-based software and solution provider.
“We literally searched the world for the strategic partner who shares the same passion as we do and would closely work with us to bring these ideas to reality. We’re fortunate to have found what we were looking for in Aplix of Japan, a world leader in Bluetooth and Wi-Fi design, development and manufacture of related components,” says OurPet’s CEO Dr. Steve Tsengas. “OurPet’s and Aplix have invested extensive resources to develop new products fueled by smart technology and we look forward to collaborations that continue this development.”
The approximately 85.5 million domesticated cats and 77.8 million domesticated dogs in the U.S. are considered a primary part of the family, with owners spending an increasing amount of time and money on their pets in the home. According to the American Pet Products Association (APPA), this bond translates to growth within the U.S. pet industry from $16 billion to over $60 billion during the last 20 years alone.
OurPet’s is cognizant of this growth, and of the fact that pet owners are looking for ways to improve their relationship and “communicate with their pets” by providing a harmonious, healthy experience and home for the animal. The goal of OurPet’s agreement with Aplix is to employ the technology related to Bluetooth and Wi-Fi to develop products that satisfy all these objectives.
Aplix will work with OurPet’s to help the company further develop its innovative product lines in the lucrative pet supply industry. “Aplix is very excited to closely collaborate with the OurPet’s innovative team in the design/development of future product lines,” says Mr. Ryu Koriyama, the Aplix President who, early in his career, has worked for companies such as Microsoft, founded by Bill Gates, and NeXT, founded by Steve Jobs.
Since its launch in 1995, OurPet’s has been an active trend setter in the pet industry. The launch of the patented “Big Dog Feeder®” and subsequent other elevated feeders successfully established healthy feeding trends. The launch of the company’s patented electronic “Play-N-Squeak®” cat toy established interactive, physical/mental pet toys, while the launch of the “Durapet®” stainless steel bowls with a non-skid rubber molded base transitioned feeding bowls into a non-commodity expression of fashion and love. More recently, OurPet’s product innovation has focused on waste and odor control with the patented SmartScoop® automated, highly reliable, cost effective litter box and the EZ Scoop™ semi-automatic litter box.
Today, OurPet’s has more than 160 issued or pending patents and derives over 75% of its revenue from proprietary products. True innovation works in tandem with evolution, and OurPet’s has no intention of leaving its innovative success cemented in the past.
“We have experienced rapid growth in sales and profits by means of a simple strategy — listening to pet owners and retailers and applying our extensive knowledge related to pet behavior, geriatrics and nutrition and the extensive engineering technology/manufacturing,” says Dr. Tsengas. “We’re excited to see where this new strategic partnership takes us.”
About Aplix
Aplix IP Holdings Corporation is a unique company listed on the Tokyo Stock Exchange. Originally founded as Aplix Corporation in 1986, Aplix has developed and provided multimedia authoring systems for the NeXT Computer System, CD and DVD mastering software for Apple Macintosh and Appcessory software for iOS devices. In 2009, Aplix acquired Zeemote Inc., a Bluetooth hardware company which was founded in 2005 by MIT graduates. Aplix’s mission is to make the benefits of Internet of Things available to everyone, everywhere and on everything by designing and offering easy-to-use, yet affordable wireless connectivity solutions to bring value to all sectors of the market. As a leading solution provider for consumer electronic products with a proven track record for nearly 30 years, Aplix understands that the customers’ needs go beyond connectivity. Therefore, Aplix has gone the extra mile, combining their high-quality radio modules and advanced network technology to develop a comprehensive solution that provides insight into consumer behavior and enhances the usage of their customers’ products. Aplix’s passion is building strong partnerships with their customers to create a new business model for the Internet of Things.
About The OurPet’s Company
The OurPet’s Company (OTCQX: OPCO) designs, produces and markets a broad line of innovative, trend-setting pet products and accessories sold under the OurPets and Pet Zone brands domestically and internationally. OurPets and Pet Zone products are sold through leading pet specialty retailers, food, drug and mass merchandisers, direct-mail catalog and internet retailers. Since its founding in 1995, the OurPet’s Company has been building an extensive intellectual property portfolio with more than 160 patents in either issued or pending status all devoted to solving problems related to the human/pet bond. OurPet’s was named a Weatherhead Top 100 Fastest Growing Company in Northeast Ohio in 2013 and has been a Lake-Geauga County Fast Track 50 Hall of Fame local business success winner for the last eight consecutive years. In addition, the OurPet’s Company was named 2015 Business of the Year by the Painesville Area Chamber of Commerce. Investors and customers may visit www.ourpets.com and www.petzonebrand.com for more information about the Company, its products and brands.
Contact:
Peter Ostapowicz
Marketing Coordinator
postapowicz@ourpets.com
TraderPower Featured Companies
Top Small Cap Market News
- $SOBR InvestorNewsBreaks – SOBR Safe Inc. (NASDAQ: SOBR) Closes on $8.2M Private Placement
- $CLNN InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
Recent Posts
- $EAWD IEA Hosts G20 Ministers, Influential Personalities to Discuss Clean and Affordable Energy Transition
- $SFWJ InvestorNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses
- $RFLXF JPMorgan Executive Says US Backlash Against ESG Is Exaggerated
- $TMET.V Gold Stutters as Strong US Jobs Data Dampens Expectations of Large Rate Cuts
- $FSTTF InvestorNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTC: FSTTF) Shares Additional Information on the PyroDelta Thermoelectric Generator, Relationship with Subsidiary
- $LEXX InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
- $LGVN InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at This Month’s Congenital Heart Surgeons’ Society Annual Meeting
- $ATBHF Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) Releases Updated Report on Storm Copper Project Drilling Program
Recent Comments
Archives
- October 2024
- January 2023
- June 2022
- December 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009